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ABSTRACT
The present study was undertaken to examine the status of antimicrobial resistance in Salmonella-associa-
ted diseases, by verifying possible emergence of reduced susceptibility to fluoroquinolones in Salmonella 
isolates and determining the incidence of Plasmodium falciparum-associated co-infection with Salmonella 
serotypes. Antimicrobial resistance in clinical isolates of Salmonellae was examined for a 12-month pe-
riod. Four hundred and forty-one patients comprising two groups were recruited. Group A comprised 235 
patients diagnosed by clinicians of having pyrexia, and group B included stool samples of 206 patients 
presenting with gastroenteritis. Samples were cultured and isolates identified, and drug susceptibility test-
ing was performed using the standard methods. Of the 235 samples screened in group A, 42 Salmonella 
isolates and 107 Plasmodium spp. were identified. Of the 42 Salmonella isolates, 19 (45.2%) were Salmonella 
Typhi, 9 (21.4%) S. Enteritidis, and 7 (16.7%) each of S. Paratyphi and S. Arizonae. Plasmodium spp.-as-
sociated co-infection with Salmonellae was observed in 16 patients mostly in complicated typhoidal cases 
and S. Enteritidis-associated bacteraemia. Fiftty-three of the 206 stool samples from group B patients were 
confirmed positive for bacterial pathogens, made up of 35 Salmonella and 18 Shigella isolates. Of the Salmo-
nella isolates, 18 (51.4%) were S. Enteritidis, 11 (31.4%) S. Arizonae, 4 (11.4%) S. Paratyphi, and 2 (5.7%) S. 
Typhi. There was no statistically significant difference (p<0.01) in antimicrobial resistance patterns exhibi-
ted among typhoidal Salmonellae isolated in 2000 and 2005. A similar trend in resistance was recorded for 
non-typhoidal Salmonellae (p<0.05). For the first time in Lagos, Nigeria, Salmonella isolates (10-18%) with 
reduced susceptibility to both ciprofloxacin and ofloxacin at MIC50 and MIC90 values of 0.015 and 0.03 
µg/mL respectively were found. Despite this development, ciprofloxacin and ofloxacin remain the drug of 
choice for severe cases of salmonellosis, although caution should be exercised by clinicians in their pres-
criptions such that fluoroquinolone antibiotic therapy is used only in laboratory-proven cases of typhoid 
fever and Salmonella-associated bacteraemia to preserve its efficacy.
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INTRODUCTION
Salmonella, a genus of Gram-negative rod-shaped 
bacteria of the family Enterobacteriaceae, causes a 
wide range of human diseases, such as enteric fe-
ver, gastroenteritis, endocarditis, and bacteraemia 
(1). Salmonella-associated infections do not present 
with distinct clinical features: other bacterial, viral 
and even protozoans may mimic its presentations Akinyemi KO et al. Antimicrobial resistance among Salmonella serotypes
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(2). More than 2,300 Salmonella enterica serotypes 
have been described. Only S. enterica serovar Ty-
phi, S. Paratyphi, S. Typhimurium, S. Enteritidis, S. 
Choleraesuis, S. Hadar, S. Virchow, and S. Dublin, 
among others, play important epidemiological and 
epizootiological roles (3). Although infections with 
non-typhoidal Salmonellae usually cause self-limi-
ted diarrhoeal illness, serious sequelae, including 
meningitis, sepsis, and death, may occur, especially 
among infants and elderly persons (4).
Adequate sanitary measures have led to a decrease 
in cases of typhoidal Salmonellae in developed 
countries, such as the USA and the UK, where the 
incidence is low, and most cases are associated with 
travellers returning from endemic areas of develop-
ing countries (5). However, in these countries, non-
tyhoidal  salmonellosis  is  common,  and  most  of 
these cases are associated with outbreaks from con-
taminated meat, dairy products, and/or by cross-
contamination from foods contaminated with 
Salmonellae (6,7). The situation is different in deve-
loping countries of Africa and southern Asia where 
typhoidal salmonellosis continues to pose a threat 
to public health with an estimated incidence of 33 
million cases each year (8,9). In Nigeria, morbidity 
associated with illnesses due to Salmonella continues 
to be on the increase and, in some cases, resulting 
in death. Like other countries, treatment of patients 
has been based on the use of first-line antibiotics, 
such as chloramphenicol and co-trimoxazole, and 
the third-generation cephalosporins. However, ef-
ficacies of some of these drugs have been doubtful, 
following the emergence of multidrug resistance in 
Salmonella strains (10,11). Fluoroquinolones have 
been found to be efficacious both in vitro and in 
vivo in the treatment of severe Salmonella-associa-
ted illnesses, although strains with reduced sus-
ceptibility to ciprofloxacin among travellers have 
been reported in some parts of the globe (12). In 
malaria-endemic region, such as Nigeria, there ex-
ists an association between falciparum malaria and 
Salmonella-associated bacteraemia. Factors, such as 
improper sewage disposal, poor personal hygiene, 
poverty, and rapidly-increasing urbanization, have 
been attributed to frequent cases and deaths arising 
from these diseases (2,13-15).
Thus, high rate of hospitalization and prolonged 
illness of patients with Salmonella-associated dis-
eases, as a result of treatment failure with empirical 
therapy, has been a great concern to public health. 
Active surveillance on salmonellosis in recent years 
is rare. Besides, there is a paucity of data on co-in-
fection of Salmonellae with the malaria parasite in 
Nigeria. The present study was undertaken to 
examine the status of antimicrobial resistance in 
Salmonella-associated diseases, verifying possible 
emergence of reduced susceptibility to fluoroqui-
nolones in Salmonella isolates and determining the 
incidence of Plasmodium falciparum-associated co-
infection with Salmonella serotypes.
MATERIALS AND METHODS
Patient population, case definition, and 
sample collections
Four-hundred and forty-one patients, made up of 
group A and B were recruited for the study. They 
sought treatments at the following referral centres: 
Ikeja General Hospital, Lagos, Infectious Diseases 
Hospital Mainland, Lagos, Central Bank of Nigeria 
Clinics Satellite, Lagos, and Central Medical Labo-
ratory Health Centre, Lagos, from October 2004 
to September 2005. Important bio-data, history of 
vaccination, antimicrobial therapy, time of onset of 
illness, etc. of these patients were recorded. Group 
A comprised 235 patients diagnosed by clinicians 
of having pyrexia (temperature ≥38.5 oC) for up 
to five days with or without one or combination 
of the following symptoms: vomiting, headache, 
diarrhoea, loss of appetite, abdominal pain, and 
nausea. Only blood samples were requested from 
the patients due to the early onset of symptoms. 
Four mL of blood was collected from each patient. 
Of this, 1 mL of blood was transferred into a ster-
ile EDTA bottle and kept at 4 oC until the malaria-
parasite test was performed. The remaining 3 mL of 
blood was directly inoculated into 27 mL of brain 
heart infusion (BHI) broth (Oxoid, UK) for bacte-
riological culture. Group B comprised 206 patients 
who sought medical care due to passing of frequent 
stool (diarrhoea) for two or more days without fe-
ver. Fresh stool samples were collected from this cate-
gory of patients in Cary-Blair tubes (10 mL/tube), 
and the tubes containing samples were transported 
to the laboratory for bacteriological culture.
Bacteriology and malariology
Stool samples were cultured on MacConkey (MC) 
agar, desoxycholate citrate (DC) agar, Salmonella-
Shigella (SS) agar, and Selenite F broth (Oxoid, UK). 
Media were incubated overnight at 37 oC, and non-
fermenting lactose colonies of different morphologi-
cal types growing on SS agar, DC agar, or MC agar 
plates were identified based on their biochemical 
properties. The BHI broth-culture bottles were ino-
culated at 37 oC aerobically for 18-24 hours. Subcul-
tures were made onto solid media plates of SS agar, Akinyemi KO et al. Antimicrobial resistance among Salmonella serotypes
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MC agar, and DC agar and were further incubated at 
37 oC aerobically for 18-24 hours. In negative cases, 
subcultures were repeated from the broth daily for 
seven consecutive days and were then discarded. 
Colonies were first subjected to biochemical tests 
as described by Cowan and Steel (16). The com-
mercially-available identification system—API 20E 
(bio-Mérieux, France)—was used. Colonies consid-
ered to be of Salmonella spp. were further tested for 
somatic (O) and flagella (H) antigens with polyva-
lent antisera (Wellcome Diagnostic, UK). For each 
patient, a 1 mL of blood sample was screened using 
the thick-blood smear technique for the detection 
of malaria parasite (17). Blood smear was prepared 
and air-dried. Freshly-prepared Giemsa stain was 
added, left for 45 minutes, and then rinsed off un-
der slow-running tap-water. The slide was observed 
under an oil immersion lens for evidence of Plas-
modium spp.
Antimicrobial susceptibility testing and  
determination of minimum inhibitory  
concentration
Susceptibility patterns of Salmonella serotypes to 13 
antibiotics were determined by the agar-diffusion 
method (18). Three to five colonies were inoculated 
into a tube containing tryptic soy broth (Difco, USA) 
and incubated overnight at 37 oC. Standardization 
of the inocula was performed by diluting the broth 
cultures until turbidity matched the 0.5 McFarland 
standards. A sterile cotton swab was dipped into 
the standardized suspension, drained, and used for 
inoculating 20 mL of Mueller-Hinton agar in a 100-
mm disposable plate (Sterlin, UK). The inoculated 
plates were air-dried, and antibiotic discs (Oxoid, 
UK) were placed on the agar using flamed forceps 
and were gently pressed down to ensure contact. 
The discs with the following were used for suscepti-
bility testing: ampicillin (25 µg), chloramphenicol 
(30 µg), co-trimoxazole (25 µg), tetracycline (50 
µg), nalidixic acid (30 µg), ciprofloxacin (20 µg), 
ofloxacin (20 µg); colistin-sulphate (10 µg), strepto-
mycin (25 µg), gentamicin (10 µg), cefotaxime (30 
µg), cefoperazone (30 µg), and amoxicillin (30 µg). 
The plates were incubated aerobically at 37 oC for 
18-24 hours. The diameters of the zones of inhi-
bition were measured with a ruler and compared 
with a zone-interpretation chart (18). Escherichia 
coli ATCC 25922 was used as control. The determi-
nation of MIC was performed using the reference 
broth microdilution method recommended by the 
National Committee for Clinical Laboratory Stan-
dards (19). The reagent powders were dissolved in 
accordance with the instructions of the manufac-
turer (Sigma, Deisenhofen, Germany), diluted with 
Mueller-Hinton broth, and distributed to the wells 
of microdilution trays. Each tray was inoculated 
with approximately 5x105 CFU per well to yield a 
final volume of 0.l mL per well. The trays were in-
cubated at 35 °C for 18 hours. E. coli ATCC 25922 
was used as control strain in each test batch. MIC 
was taken as the highest dilution of the antibiotic 
that yielded no visible bacterial growth (no turbid-
ity) when compared with the control. Thereafter, 
MIC50 and MIC90 were evaluated accordingly (20). 
RESULTS
Of the 235 samples screened in group A patients, 
42 Salmonella isolates and 107 Plasmodium spp. 
were identified. Of the 42 Salmonella isolates, S. Ty-
phi was the most frequently-encountered serotype 
accounting for 45.2%, followed by S. Enteritidis 
(21.4%) (Table 1). Sixteen Salmonella spp. made up 
of seven each of S. Typhi and S. Enteritidis, and 
two of S. Paratyphi were isolated with Plasmodium 
spp. from patients with complications. These dual 
infections occurred in all age-groups studied, with 
predilection in the age-group of 16-30 years (Table 
2). Fiftty-three of the 206 stool samples from group 
B  patients  were  confirmed  positive  for  bacterial 
pathogens, made up of 35 Salmonella and 18 Shigel-
la isolates. Of the Salmonella isolates, S. Enteritidis 
(51.4%) was the most prevalent serotype. Other se-
rotypes isolated were S. Arizonae (31.4%), S. Paraty-
phi (11.4%), and S. Typhi (5.7%) (Table 1). Salmonel-
lae were isolated in each month from October 2004 
to September 2005 with the peak incidence in May, 
June, and February. The least cases of Salmonella–as-
sociated illnesses occurred in March and December 
(Fig. 1). In this study, S. Typhi and S. Paratyphi were 
100% resistant to ampicillin, approximately 90% 
to tetracycline, and 80% to chloramphenicol and 
gentamicin. The resistance of both the serotypes 
to cefotaxime, streptomycin, and co-trimoxazole 
ranged from 51.5% to 70%. Moreover, less than 
20% reduced susceptibility to fluoroquinolones 
(ciprofloxacin and ofloxacin) was observed in both 
the serotypes. Similar antibiotic resistance patterns 
were observed and recorded for non-typhoidal Sal-
monellae isolated in the study (Table 3). Minimum 
inhibitory concentrations (MICs) of each of the 13 
antibiotics that constituted 50% and 90% Salmo-
nellae susceptible in vitro are shown in Table 4. For 
example, fluoroquinolones inhibited the growth of 
50% and 90% of the isolates at 0.015 and 0.03 µg/
mL respectively, whereas a wide variation in MIC50 
and MIC90 values was recorded for other antibio-
tics, particularly ampicillin, chloramphenicol, and 
tetracycline, in the study.Akinyemi KO et al. Antimicrobial resistance among Salmonella serotypes
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Table 1. Absolute figures and percentages of pathogens isolated according to the source
Source 
(sample 
size)
No. of 
positive 
samples
Salmonella enterica serotypes isolated
Other pathogens  ob-
tained (% from total 
positive samples)
No. of 
isolates
S. Typhi S. Paratyphi S. Enteritidis S. Arizonae Plasmodium 
spp.
Shigella  
spp.
Blood
(235)
152 (74.2) 42 (27.6) 19 (45.2) 7 (16.7) 9 (21.4) 7 (16.7) 107 (70.4) 3 (2.0)
Stool
(206)
53 (25.8) 35 (66.0) 2 (5.7) 4 (11.4) 18 (51.4) 11 (31.4) NA 18 (34.0)
Total 205 (100) 77 (100) 21 (27.3) 11 (14.3) 27 (35.1) 18 (23.4) NA 21 (10.2)
Figures in parentheses indicate percentages; NA=Not applicable
Table 2. Relative risk of co-infection due to Salmonellae with Plasmodiun spp. in different  
age-groups of patients with pyrexia studied
Age-groups
(years)
Patients with Plasmodium spp. (n=107) Patients with Salmonellae (n=42)
Co-infection of 
patients with 
Salmonella spp. 
(n=16)
Without Salmonella 
spp. (n=91)
Co-infection of 
patients with 
Plasmodium spp. 
(n=16)
Without  Plasmo-
dium spp. (n=26)
0-5
6-15
16-30
31-45
>46
2
3
5
4
2
27
28
17
11
8                       
2
3
5
4
2
1
7
            10
4
4
Table 3. Comparison and percentage of resistant Salmonella serotypes to 13 antibiotics in two  
different studies from Lagos
Antibiotic used
Percentage of Salmonella serotypes in 2000* and the present study
       S. Typhi       S. Paratyphi           S. Arizonae S. Enteritidis†
2000* 
(n=68)
Present 
study 
(n=21)
2000* 
(n=17)
Present 
study 
(n=11)
2000*
(n=16)
Present 
study
(n=18)
Present study
(n=27)
Ampicillin
Co-trimoxazole
Chloramphenicol
Gentamicin
Tetracycline
Streptomycin
Cefotaxime
Nalidixic acid 
Ciprofloxacin
Ofloxacin
Colinstin sulphate
Amoxicillin
Cefoperazone
91.2
61.8
73.5
29.4
64.7
32.4
51.5
13.2
0.0
0.0
44.1
ND
ND
100
71.4
85.7
81.0
90.5
66.7
66.7
38.1
14.3
14.3
52.4
57.1
57.1
   88.2
   64.7
   70.6
   29.4
   64.7
   35.3
   35.3
   17.7
     0.0
     0.0
   41.2
    ND
    ND
   100
   63.6
   81.8
   81.8
   90.1
   63.6
   54.5
   27.3
   18.2
   18.2
   27.3
   63.6
   72.3
   93.8
   56.3
   87.5
   31.3
   68.8
   37.5
   31.5
   12.5
    0.0
    0.0
  37.5
   ND
   ND
  100
  61.1
  88.9
  83.3
  88.9
  72.2
  55.5
  27.8
  11.1
  11.1
  55.6
  55.6
  61.1
      100
      85.2
      85.2
      88.9
      92.6
      59.3
      59.3
      33.3
      14.8
      14.8
      40.7
      59.3
      55.6
*Data obtained from reference (10); †Data not available; ND=Not determined; n=Number of  
isolates evaluatedAkinyemi KO et al. Antimicrobial resistance among Salmonella serotypes
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Table 4. Minimun inhibitory concentrations (µg/mL) of 13 antibiotics each tested against  
Salmonella species isolated
Antibiotics used (break-
point for resistance)
Typhoidal Salmonellae (n=32) Non-typhoidal Salmonellae (n=45)
Range MIC50 MIC90 Range MIC50 MIC90
Ampicillin (≥32)
Co-trimoxazole (≥32)
Chloramphenicol (≥16)
Gentamicin (≥8)
Tetracycline (≥8)
Streptomycin (≥32)
Cefotaxime (≥64)
Nalidixic acid (≥8)
Ciprofloxacin (≥4)
Ofloxacin (≥8)
Colinstin sulphate (≥8)
Amoxicillin (≥32)
Cefoperazone (≥64)
64-128
0.25-64
1-64
4-64
4-128
1-128
32-64
1-64
0.003-1
0.003-1
1-128
1-32
4-64
  64.0
  16.0
  64.0
   1.0
  64.0
  64.0
  64.0
   8.0
   0.015
   0.015
  32.0
  32.0
  64.0
 128.0
   64.0
   64.0
   32.0
 128.0
 128.0
   64
  16.0
   0.03
   0.03
  64.0
  32.0
  64.0
  64-128 
  0.25-64
  0.25-64
  0.25-16
  1-64
  1-128
  16-64
  1-32
  0.003-1
  0.003-1
  1-64
  1-32
  1-64
  64.0
  16
  32
  16
  16
  64
  64
  8.0
  0.015
  0.015
  32
  32
  64
  64.0
  64.0
  32
  16
  32
  64
  64
  16
  0.03
  0.03
  32
  32
  64
Fig. 1. Monthly isolation of Salmonella strains from patients in Lagos, October 2004–September   2005
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DISCUSSION
Seventy-seven Salmonella strains, which included 
42  (17.8%)  from  blood  of  patients  with  pyrexia 
and 35 (17.0%) from stool samples of patients with 
gastroenteritis, were isolated in the study, given 
an incidence of 17.5% of Salmonella-associated ill-
nesses for the 12-month period. The results of the 
study indicated that the frequency of isolation of 
S. Typhi (45.2%) from patients with pyrexia has 
not changed from the previous report in Lagos in 
which 105 Salmonella isolates, made up of 67.3% 
S. Typhi, 16.8% S. Paratyphi, and 15.8% S. Arizo-
nae, were obtained (10). The high prevalence was 
similar to non-typhoidal salmonellosis reported in 
Malawian and Tanzanian patients (21) and S. Typhi 
mostly implicated in India, South East Asia, and 
Latin America (9,12). 
Despite a high endemic nature of malaria in Nige-
ria, information on Salmonella spp.-associated co-Akinyemi KO et al. Antimicrobial resistance among Salmonella serotypes
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infection with Plasmodium spp. is scarce. We found 
in the blood of 16 patients Plasmodium spp.-asso-
ciated co-infection with Salmonella isolates distrib-
uted  among  the  age-groups  examined.  Seven  of 
16 each were S. Typhi and S. Enteritidis serotypes, 
while the rest were S. Paratyphi. The fact that these 
Salmonella serotypes were isolated from the blood 
of the pyrexia patients ruled out the possibilities 
that these individuals might be carriers. Previous 
workers elsewhere had documented an association 
between falciparum malaria and Salmonella-associa-
ted bacteraemia in malaria-endemic regions (15). 
Similarly, co-infections of bacteria in the family 
Enterobacteriaeciae with falciparum malaria have 
been  reported  in  some  malaria-endemic  African 
countries (22,23). Our results were consonant with 
findings of these studies, thus representing the first 
published case in Lagos, Nigeria. Furthermore, we 
observed that nine of the 16 patients with dual 
infections suffered from serious typhoid and para-
typhoid  fever-related  complications,  such  as  de-
lirium, confusion, coma, and spleenomegaly. Also, 
co-infection of Plasmodium spp. with S. Enteritidis-
associated bacteraemia was observed in seven pa-
tients in this study. Generally, these observations 
could be associated with the fact that Salmonella-
associated infection exacerbates infection due to P. 
falciparum and, thus, might account for complica-
tions in these patients. P. falciparum increases the 
risk of complications via a number of mechanisms, 
including immune dysfunctions (24). We also ob-
served that 16 Salmonella isolates with P. falciparum-
associated co-infection were resistant to eight or 
more antibiotics, including the third-generation 
cephalosporins. The implication of this is treatment 
failure and the probable emergence of multiple an-
timicrobial resistance in Salmonella strains.
There was no statistically significant difference 
(p<0.01) in the patterns of antimicrobial resistance 
in typhoidal Salmonellae isolated from cases of 
pyrexia in the present study and that of previous 
years (Table 4). However, the first decreased suscep-
tibility to fluoroquinolones in Salmonella isolates at 
MIC50 and MIC90 values of 0.015 and 0.03 µg/mL 
respectively in Nigeria was recorded in this study. 
This observation is a concern as the only hope of 
therapy for typhoid fever and complicated cases of 
non-typhoidal salmonellosis in our environment 
is now threatened. Additionally, more than 51% 
of the isolates were resistant to cefotaxime and ce-
phoperazone. This trend is of particular concern 
because the extended spectrum cephalosporins are 
the antibiotics of choice for children (25). In Afri-
can countries, such as Kenya, Malawi, and Ethio-
pia, neither fluoroquinolones nor third-generation 
cephalosporin resistance among Salmonella strains 
is a problem (26). 
In Nigeria, the observed reduced susceptibility to 
fluoroquinolones is a new scourge, and the expla-
nation for this is inconclusive and difficult. This is 
because these drugs are relatively expensive as the 
cost of ciprofloxacin or ofloxacin is over $5.00 for 
a five-day therapy in adults. However, reports  else-
where have indicated that the use of antimicrobials 
for growth-promotion prophylaxis and treatment 
of food-animals increases the prevalence of resis-
tance  in  human  pathogens,  particularly  non-ty-
phoidal salmonellosis. This practice is common in 
Asia and the United Kingdom and in some other 
European countries where fluoroquinolones have 
been approved for animal use (27,28). The situa-
tion is rare in our environment. However, the in-
creasing smuggling of poultry products into our 
country, as a result of the ban in importation of 
these products in recent times, might be, among 
other factors, a likely reason for the emergence of 
reduced  susceptibility  to  fluroquinolones  in  our 
environment. There has been a suggestion that the 
use of antimicrobials in animal growth should be 
phased out gradually, since similar benefits could 
be obtained by improving other aspects of animal 
care, such as hygiene (29). Denmark voluntarily 
suspended the use of all animal growth promot-
ers in 1999 and has started yielding positive effect, 
and Switzerland also did the same in 2000 (30). It 
is saddening to say that, while these countries have 
made tremendous efforts in solving the problem of 
fluoroquinolone resistance in Salmonella serotypes, 
our environment has just witnessed the emergence 
of decreased susceptibility to fluoroquinolones in 
Salmonella isolates. The fear is that, if the trend con-
tinues, it may cause a serious public-health threat, 
thus, putting the problem into international pers-
pective. 
In conclusion, Plasmodium spp.-associated co-infec-
tion with Salmonella serotypes was observed more 
in patients with typhoidal complications and Sal-
monella-associated bacteraemia. We record the first 
reduced susceptibility of fluoroquinolones in Sal-
monella isolates in our environment. Despite this 
development, ciprofloxacin and ofloxacin remain 
the drug of choice for typhoidal and severe cases 
of non-typhoidal salmonellosis, although caution 
should be exercised by clinicians in their prescrip-
tion such that fuoroquinolone antibiotic therapy is 
used only in laboratory-proven cases to preserve its 
efficacy. More importantly, there is a need for the Akinyemi KO et al. Antimicrobial resistance among Salmonella serotypes
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Government to enforce the existing laws that pro-
hibit smuggling of all kinds and the sale of drugs by 
unauthorized people. On a global scale, the current 
efforts of the World Health Organization towards 
establishing more National Reference Laboratories 
for Infectious Diseases and Antimicrobial Surveil-
lance Centres in many countries should be inten-
sified, and such efforts should benefit developing 
countries. This may pave the way for adequate 
records, proper monitoring, and effective manage-
ment of antimicrobial resistance in a pathogen cur-
rently threatening the healthcare system. 
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